Deutsche Bank analyst Dan Leonard placed a "Buy Catalyst Call" on Genomic Health as he believes the stock's risk/reward skews positive into the German Federal Joint Committee's public meeting on June 20. An endorsement by the committee is the final gating factor to broad public reimbursement for Genomic's invasive breast cancer test in Germany, which adds a ~30,000 test opportunity, Leonard tells investors in a research note. He believes the committee is likely to issue a press release favorable to Genomic Health's iBC test on Thursday or Friday following its public meeting, which could move the stock up 5%. The analyst, however, keeps a long-term fundamental Hold rating on Genomic Health.